Src inhibitors and angiogenesis

Current Pharmaceutical Design

Volumn 13, Issue 21, 2007, Pages 2118-2128

  Schenone, S ^a   Manetti, F ^b   Botta, M ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

Angiogenesis; Binding mode; Cancer; FGF; Small molecules inhibitors; Src; Tyrosine kinase; VEGF

Indexed keywords

2,3 DIHYDRO 2 OXO 3 (4,5,6,7 TETRAHYDRO 1H INDOL 2 YLMETHYLENE) 1H INDOLE 5 SULFONIC ACID DIMETHYLAMIDE; 4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; 4 AMINO 7 TERT BUTYL 5 (4 METHYLPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; ANGIOGENESIS INHIBITOR; AP 23846; AP 23848; BENZENE DERIVATIVE; BEVACIZUMAB; CELL SURFACE RECEPTOR; CGP 76030; CGP 77675; M 475271; MATRIX METALLOPROTEINASE; PD 166285; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; PURINE DERIVATIVE; PYRAZOLO[3,4D]PYRIMIDINE DERIVATIVE; PYRIDO[2,3D]PYRIMIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLO[2,3D]PYRIMIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE; RESVERATROL; SU 11333; SU 11336; SURAMIN; THROMBOPLASTIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ARTHRITIS; BRAIN INJURY; CANCER; CANCER CHEMOTHERAPY; CAPILLARY; CELL ADHESION; CELL FUNCTION; CELL GROWTH; CELL MOTILITY; CELL PROLIFERATION; CELL TRANSPORT; DRUG ACTIVITY; DRUG MECHANISM; ENDOMETRIOSIS; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME STRUCTURE; HEMATOLOGIC MALIGNANCY; HUMAN; METASTASIS; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; REGULATORY MECHANISM; RETINOPATHY; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; TUMOR GROWTH;

ANGIOGENESIS INHIBITORS; ANIMALS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PHYSIOLOGIC; PROTEIN KINASE INHIBITORS; PURINES; PYRAZOLES; PYRIMIDINES; QUINAZOLINES; SRC-FAMILY KINASES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34447270926     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207781039580     Document Type: Review

References (123)

1. Folkman J, D'Amore P. Blood vessels formation: what is his molecular basis? Cell 1996; 87: 1153-5.
2. Risau W. Mechanism of angiogenesis. Nature 1997; 386: 671-4.
3. Klagsbrun M, Moses MA. Molecular angiogenesis. Chem Biol 1999; 6: R217-24.
4. Mantovani A, Bussolino F, Dejana E. Cytokine regulation of endothelial cell function. FASEB J 1992; 6: 2591-9.
5. Kerbel RS. Tumor angiogenesis: past, present and the near future. Carcinogenesis 2000; 21: 505-15.
6. Madhusudan S, Harris AL. Drug inhibition of angiogenesis. Curr Opin Pharm 2002; 2: 403-14.
7. Strawn LM, McMahon G, App H, Schreck R, Kuchler WR, Longhi MP, et al. Flk-1 as a target for tumor growth inhibition. Cancer Res 1996; 56: 3540-5.
8. Verheul HM, Jorna AS, Hoeckman K, Broxterman HJ, Gebbink MF, Pinedo HM. Vascular endothelial growth factor-stimulated endothelial cells promote adhesion and activation of platelets. Blood 2000; 96: 4216-21.
9. Moses MA. The regulation of neovascularization by matrix metalloproteinases and their inhibitors. Stem Cells 1997; 15: 180-9.
10. 3 integrins during angiogenesis. Mol Med 1998; 4: 741-50.
11. Zhao L, Eghbali-Webb M. Release of pro and anti-angiogenic factors by human cardiac fibroblasts: effects on DNA synthesis and protection under hypoxia in human endothelial cells. Bioch Biophys Acta 2002; 1538: 273-82.
12. Vlodavsky I, Friedmann I, Elkin M, Aingorn H, Atzmon R, Ishai-Michaeli R, et al. Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat Med 1999; 5: 793-802.
13. Benjamin LE, Herno I, Keshet E. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 1998; 125: 1591-8.
14. Folkman J. Angiogenesis inhibitors generated by tumors. Mol Med 1995; 1: 120-2.
15. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nat Med 1995; 1: 27-31.
16. Fox SB, Gasparini G, Harris AL. Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs. Lancet Oncol 2001; 2: 278-89.
17. List AF. Vascular endothelial growth factor signaling pathways as an emerging target in haematological malignancies. Oncologist 2001; 6: 24-31.
18. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:1182-6.
19. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-64.
20. Sun L, McMahon G. Inhibition of tumor angiogenesis by synthetic receptors tyrosine kinase inhibitors. Drug Discov Today 2000; 5: 344-53.
21. van Beijnum JR, Griffioen AW. In silico analysis of angiogenesis associated genes expression identifies angiogenic stage related profiles. Bioch Biophys Acta 2005; 1755: 121-34.
22. Gasparrini G. The rationale and future potential of angiogenesis inhibitors in neoplasia. Drugs 1999; 58: 17-38.
23. Griffioen AW, Molema G. Angiogenesis: potential for pharmacological intervenction in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev 2000; 52: 237-68.
24. Ruoslathi E. Specialization of tumour vasculature. Nat Rev Cancer 2002; 2: 83-90.
25. Rous PA. Transmission of a malignant new growth by means of a cell-free filtrate. JAMA 1911; 56: 198.
26. Brugge JS, Erikson RL. Identification of a transformation-specific antigen induced by an avian sarcoma virus. Nature 1977; 269: 346-8.
27. Stehelin D, Varmus HE, Bishop JM, Vogt PK. DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA. Nature 1976; 260: 170-3.
28. Neet K, Hunter T. Vertebrate non-receptor protein-tyrosine kinases families. Genes cells 1996; 1: 147-69.
29. Tsygankov AY, Bolen JB. The Src family of tyrosine protein kinases in hemopoietic signal transduction. Stem Cells 1993; 11: 371-80.
30. Roskosky RJ. Src kinase regulation by phosphorylation and dephosphorylation. Biochem Biophys Res Commun 2005; 331: 1-14.
31. Alper Ö, Bowden ET. Novel insights into c-Src. Curr Pharm Des 2005; 11: 1119-30.
32. Hanks SK, Quinn AM, Hunter T. The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science 1988; 241: 42-52.
33. Xu W, Doshi A, Lei M, Eck MJ, Harrison SC. Crystal structures of c-Src reveal features of its autoinhibitory mechanism. Mol Cell 1999; 3: 629-38.
34. Schindler T, Sicheri F, Pico A, Gazit A, Levitzki A, Kuriyan J. Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor. Mol Cell 1999; 3: 639-48.
35. Thomas JE, Soriano P, Brugge JS. Phosphorylation of c-Src on tyrosine 527 by another protein tyrosine kinase. Science 1991; 254: 568-71.
36. Cowan-Jacob SW, Fendrich G, Manley PW, Jahnke W, Fabbro D, Liebetanz J, et al. The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation. Structures 2005; 13: 861-71.
37. Breitenlechner CB, Kairies NA, Honold K, Scheiblich S, Koll H, Greiter E, et al. Crystal structures of active SRC kinase domain complexes. J Mol Biol 2005; 353: 222-31.
38. Brown MT, Cooper JA. Regulation, substrates and functions of src. Biochim Biophys Acta 1996; 1287: 121-49.
39. Roskoski RJ. Src protein-tyrosine kinase structure and regulation. Biochem Biophys Res Commun 2004; 324: 1155-64.
40. Tsygankov AY, Shore SK. SRC: regulation, role in human carcinogenesis and pharmacological inhibitors. Curr Pharm Des 2004; 10: 1745-56.
41. Soriano P, Montgomery C, Geske R, Bradley A. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 1991; 64: 693-702.
42. Levin VA. Basis and importance of Src as a target in cancer. Cancer Treat Res 2004; 119: 89-119.
43. Schlaepfer DD, Mitra SK. Multiple connections link FAK to cell motility and invasion. Curr Opin Genet Dev 2004; 14: 92-101.
44. Luttrell LM, Daaka Y, Della Rocca GJ, Lefkowitz RJ. G protein-coupled receptors mediate two functionally distinct pathways of tyrosine phosphorylation in rat 1a fibroblasts. Shc phosphorylation and receptor endocytosis correlate with activation of Erk kinases. J Biol Chem 1997; 272: 31648-56.
45. Ahn S, Maudsley S, Luttrell MN, Lefkowitz RJ, Daaka Y. Src-mediated tyrosine phosphorylation of dynamin is required for beta2-adrenergic receptor internalization and mitogen-activated protein kinase signaling. J Biol Chem 1999; 247: 1185-8.
46. Holmes TC, Fadool DA, Ren R, Levitan IB. Association of Src tyrosine kinase with a human potassium channel mediated by SH3 domain. Science 1996; 274: 2089-91.
47. Mohamed AS, Swope SL. Phosphorylation and cytoskeletal anchoring of the acetylcholine receptor by Src class protein-tyrosine kinases. Activation by rapsyn. J Biol Chem 1999; 274: 20529-39.
48. Warmuth M, Damoiseaux R, Liu Y, Fabbro D, Gray N. SRC family kinases: potential targets for the treatment of human cancer and leukemia. Curr Pharm Des 2003; 9: 2043-59.
49. Summy JM, Gallick GE. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 2003; 22: 337-58.
50. Irby RB, Mao W, Coppola D, Kang J, Loubeau JM, Trudeau W, et al. Activating SRC mutation in a subset of advanced human colon cancers. Nat Genet 1999; 21: 187-90.
51. Susa M, Glatt M, Teti A. Tumor bone diseases: molecular mechanisms and opportunities for novel treatments. Curr Med Chem Anticancer Agents 2001; 1: 313-29.
52. Azuma K, Tanaka M, Uekita T, Inoue S, Yokota J, Ouchi Y, et al. Tyrosine phosphorylation of paxillin affects the metastatic potential of human osteosarcoma. Oncogene 2005; 24: 4754-64.
53. Nixon R.R. Prion-associated increases in Src-family kinases. J Biol Chem 2005; 280: 2455-62.
54. Klein NP, Bouchard MJ, Wang LH, Kobarg C, Schneider RJ. Src kinases involved in hepatitis B virus replication. EMBO J 1999; 18: 5019-27.
55. Raung S, Chen S, Liao S, Chen J, Chen C. Tyrosine kinase inhibitors attenuate Japanese encephalitis virus-induced neurotoxicity. Biochem Bhiophys Res Comm 2005; 327: 399-406.
56. Frame M. Src in cancer: deregulation and consequences for cell behaviour. Biochim Biophys Acta 2002; 1602: 114-30.
57. Lesslie DP III, Gallick GE. Src family kinases as regulators of angiogenesis: therapeutic implications. Curr Cancer Ther Rev 2005; 1: 45-50.
58. Stoker AW, Hatier C, Bissel MJ. The embryonic environment strongly attenuates v-Src oncogenesis in mesenchymal and epithelial tissues, but not in endothelia. J Cell Biol 1990; 111: 217-28.
59. Schlessinger J. New roles in Src kinases in control of cell survival and angiogenesis. Cell 2000; 100: 293-6.
60. Millauer B, Wizigmann-Voos S, Schnurch H, Martinez R, Moller NP, Risau W, et al. High affinity VEGF binding and developmental expression suggest Flk-I as a major regulator of vasculogenesis and angiogenesis. Cell 1993; 72: 835-46.
61. Chou MT, Wang J, Fujita DJ. Src kinase becomes preferentially associated with the VEGFR, KDR/Flk-I, following VEGF stimulation of vascular endothelial cells. BMC Biochem 2002; 3: 32.
62. Jiang BH, Agani F, Passaniti A, Semenza GL. V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res 1997; 57: 5328-35.
63. Jośko J, Mazurek M. Transcription factor having impact on vascular endothelial growth factor (VEGF) gene expression in angiogenesis. Med Sci Monit 2004; 10: RA89-98.
64. Sato H, Sato M, Kanai H, Uchiyama T, Iso T, Ohyama Y, et al. Mitochondrial reactive oxygen species and c-Src play a critical role in hypoxic response in vascular smooth muscle cells. Cardiovascular Res 2005; 67: 714-22.
65. Mukhopadhyay D, Tsiokas L, Zhou XM, Foster D, Brugge JY, Sukhatme VP. Hypoxic induction of human vascular endothelial growth factor expression trough c-Src activation. Nature 1995; 375: 577-81.
66. Fleming RY, Ellis LM, Parikh NU, Liu W, Staley CA, Gallick GE. Regulation of vascular endothelial growth factor expression in human colon carcinoma cells by activity of Src kinase. Surgery 1997; 122: 501-7.
67. Ellis LM, Staley CA, Liu W, Fleming RYD, Parikh NU, Bucana CD, et al. Down-regulation of vascular endothelial growth factor in a human colon carcinoma cell line transfcted with an antisense vector specific for c-Src. J Biol Chem 1998; 273: 1052-7.
68. Pal S, Datta K, Mukhopadhyay D. Central role of p53 on regulation of vascular permeability factor/vascular endothelial growth factor (VPF/ VEGF) expression in mammary carcinoma. Cancer Res 2001; 61: 6952-7.
69. Eliceiri BP, Paul R, Schwartzberg PL, Hod JD, Leng J, Cheresh DA. Selective requirements for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol Cell 1999; 4: 915-24.
70. Paul R, Zhang ZG, Eliceiri BP, Jiang Q, Boccia AD, Zhang RL, et al. Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke. Nat Med 2001; 7: 222-7.
71. Zhang ZG, Zhang L, Jiang Q, Zhang R, Davies K, Powers C, et al. VEGF enhances angiogenesis and promotes blood-barrier leakage in the ischemic brain. J Clin Invest 2000; 106: 829-38.
72. Abu-Ghazaleh R, Kabir J, Jia H, Lobo M, Zachary I. Src mediates stimulation by vascular endothelial growth factor of the phosphorylation of focal adhesion kinase at tyrosine 861, and anti-apoptosis in endothelial cells. Biochem J 2001; 360: 255-64.
73. Baldanzi G, Mitola S, Cutrupi S, Filigheddu N, van Blitterswijk W, Sinigaglia F, et al. Activation of diacylglycerol kinase α is required for VEGF-induced angiogenic signaling in vitro. Oncogene 2004; 23: 4828-38.
74. Ni G, Wright KL, Huang M, Song L, Haura E, Turkson J, et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 2002; 21: 2000-8.
75. Yu H, Jove R. The STATs of cancer-New molecular target come of age. Nature Rev Cancer 2004; 4: 97-105.
76. Xu Q, Briggs J, Park S, Niu G, Kortylewski M, Zhang S, et al. Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signalling pathways. Oncogene 2005; 24: 5552-60.
77. Sounni NE, Roghi C, Chabottaux V, Janssen M, Munaut C, Maquoi E, et al. Up-regulation of vascular endothelial growth factor-A by active membrane-type 1 matrix metalloproteinase through activation of Src-tyrosine kinases. J Biol Chem 2004; 279: 13564-74.
78. Recchia I, Rucci N, Festuccia C, Bologna M, MacKay AR, Migliaccio S, et al. Pyrrolopyrimidine c-Src inhibitors reduce growth, adhesion, motility and invasion of prostate cancer cells in vitro. Eur J Cancer 2003; 39: 1927-35.
79. McMullen M, Keller R, Sussman M, Pumiglia K. Vascular endothelial growth factor-mediated activation of p38 is dependent upon Src and RAFTK/Pyk2. Oncogene 2004; 23: 1275-82.
80. Summy JM, Trevino JG, Baker CH, Gallick GE. c-Src regulates constitutive and EGF-mediated VEGF expression in pancreatic tumor cells through activation of phosphatidyl inositol-3 kinase and p38 MAPK. Pancreas 2005; 31: 263-74.
81. Senger DR, Claffey KP, Benes JE, Perruzzi CA, Sergiou AP, Detmar M. Angiogenesis promoted by vascular endothelial growth factor: regulation through α1β1 and α2β1 integrins. Proc Nat Acad Sci USA 1997; 94: 13612-7.
82. Liu Y, Senger DR. Matrix-specific activation of Src and Rho initiates capillary morphogenesis of endothelial cells. FASEB 2004; 18: 457-68.
83. Fredriksson JM, Lindquist JM, Bronnikov GE, Nedergaard J. Norepinefrine induces vascular endothelial growth factor gene expression in brown adipocytes through a β-adrenoreceptor/cAMP/protein kinase, a pathway involving Src but independently of Erk1/2. J Biol Chem 2000; 75: 13802-11.
84. Kilarski WW, Jura N, Gerwins P. Inactivation of Src family kinases inhibits angiogenesis in vivo: implication for a mechanism involving organization of the actin cytoskeleton. Exp Cell Res 2003; 291: 70-82.
85. Marx M, Perlmutter MA, Madri JA. Modulation of platelet-derived growth factor receptor expression in microvascular endothelial cells during in vitro angiogenesis. J Clin Invest 1994; 93: 131-9.
86. c-src modulates microvascular endothelial phenotype and in vitro angiogenesis. Exp Mol Pathol 2001; 70: 201-13.
87. Kim YM, Kim YM, Lee YM, Kim HS, Kim JD, Choi Y, et al. TNF-related activation-induced cytokine (TRANCE) induces angiogenesis through the activation of Src and phospholipase C (PLC) in human endothelial cells. J Biol Chem 2002; 277: 6799-805.
88. Versteeg HH, Hoedemaeker I, Diks SH, Stam JC, Spaargaren M, van Bergen en Henegouwen PM, et al. Factor VIIa/Tissue Factor-induced signalling via activation of Src-like kinases, phosphatidylinositol 3-kinase, and Rac. J Biol Chem 2000; 275: 28750-6.
89. Kock AE, Halloran MM, Haskell CJ, Shah MR, Polverini PJ. Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1. Nature 1995; 376: 517-9.
90. Kumar P, Amin MA, Harlow LA, Polverini PJ, Koch AE. Src and phosphatidylinositol 3-kinase mediate soluble E-selectin-induced angiogenesis. Blood 2003; 101: 3960-8.
91. Polykratis A, Katsoris P, Courty J, Papadimitriou E. Characterization of heparin affin regulatory peptide signalling in human endothelial cells. J Biol Chem 2005; 280: 22454-61.
92. Trevino JG, Summy JM, Gray MJ, Nilsson MB, Lesslie DP, Baker CH, et al. Expression and activity of Src regulate interleukin-8 expression in pancreatic adenocarcinoma cells: implication for angiogenesis. Cancer Res 2005; 65: 7214-22.
93. Lee L, Louie MC, Desai SJ, Yang J, Chen HW, Evans CP, et al. Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK. Oncogene 2004; 23: 2197-205.
94. Stout TJ, Foster PG, Matthews DJ. High-throughput structural biology in drug discovery: protein kinases. Curr Pharm Des 2004; 10: 1069-82.
95. Parang K, Sun G. Recent advances in the discovery of Src kinases inhibitors. Expert Opin Ther Patents 2005; 15: 1183-207.
96. Wu SY, McNae I, Kontopidis G, McClue SJ, McInnes C, Stewart KJ, et al. Discovery of a novel family of CDK inhibitors with the program LIDAEUS: structural basis for ligand-induced disordering of the activation loop. Structure 2003; 11: 399-410.
97. Boschelli DH, Boschelli F. Small molecule inhibitors of Src family kinases. Drug Future 2000; 25: 717-36.
98. Hanke JH, Gardner JP, Dow RL, Changelian PS, Brissette WH, Weringer EJ, et al. Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation. J Biol Chem 1996; 271: 695-701.
99. Amoui M, Draber P, Draberova L. Src family-selective tyrosine kinase inhibitor, PP1, inhibits both Fc epsilonRI- and Thy-1-mediated activation of rat basophilic leukemia cells. Eur J Immunol 1997; 27: 1881-6.
100. Liu Y, Bishop A, Witucki L, Kraybill B, Shimizu E, Tsien J, et al. Structural basis for selective inhibition of Src family kinases by PP1. Chem Biol 1999; 6: 671-8.
101. Karni R, Mizrachi S, Reiss-Sklan E, Gazit A, Livnah O, Levitzki A. The pp60c-Src inhibitor PP1 is non-competitive against ATP. FEBS Lett 2003; 537: 47-52.
102. Schenone S, Bruno O, Bondavalli F, Ranise A, Mosti L, Menozzi G, et al. Antiproliferative activity of 1-aryl-4-amino substituted 1H-pyrazolo[3,4-d]pyrimidine derivatives toward the human epidermoid carcinoma A431 cell line. Eur J Med Chem 2004; 39: 939-46.
103. Donnini S, Monti M, Castagnini C, Solito R, Botta M, Schenone S, et al. Pyrazolo-pyrimidine-derived c-Src inhibitor reduces angiogenesis and survival of squamous carcinoma cells by suppressing vascular endothelial growth factor production and signaling. Int J Cancer 2007; 120: 995-1004.
104. Missbach M, Jeschke M, Feyen J, Müller K, Glatt M, Green J, et al. A novel inhibitor of the tyrosine kinase Src suppresses phosphorylation of its major cellular substrates and reduces bone resorption in vitro and in rodent models in vivo. Bone 1999; 24: 437-49.
105. Recchia I, Rucci N, Funari A, Migliaccio S, Taranta A, Longo M, et al. Reduction of c-Src activity by substituted 5,7-diphenyl-pyrrolo [2,3-d]-pyrimidines induces osteoclast apoptosis in vivo and in vitro. Involvement of ERK1/2 pathway. Bone 2004; 34: 65-79.
106. Rucci N, Recchia I, Angelucci A, Alamanou M, Del Fattore A, Fortunati D, et al. Inhibition of protein kinase c-src reduces the incidence of breast cancer metastases and increases survival in mice. implications for therapy. J Pharmacol Exp Ther 2006; 318: 161-72.
107. Laird AD, Li G, Moss KG, Blake RA, Broome MA, Cherrington JM, et al. Src family kinase activity is required for signal tranducer and activator of transcription 3 and focal adhesion kinase phosphorylation and vascular endothelial growth factor signaling in vivo and for anchorage-dependent and -independent growth of human tumor cells. Mol Cancer Ther 2003; 2: 461-9.
108. Susva M, Missbach M, Green J. Src inhibitors: drugs for the treatment of osteoporosis, cancer or both? Trends Pharmacol Sci 2000; 21: 489-95.
109. Breitenlechner CB, Kairies NA, Honold K, Scheiblich S, Koll H, Greiter E, et al. Crystal structures of active SRC kinase domain complexes. J Mol Biol 2005; 353: 222-31.
110. Summy JM, Trevino JG, Lesslie DP, Baker CH, Shakespeare WC, Wang Y, et al. AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes. Mol Canc Ther 2005; 4: 1900-11.
111. Blake RA, Broome MA, Liu X, Wu J, Gishizky M, Sun L, et al. SU6656, a selective src family kinase inhibitor, used to probe growth factor signaling. Mol Cell Biol 2000; 20: 9018-27.
112. Klutchko SR, Hamby JM, Boschelli DH, Wu Z, Kraker AJ, Amar AM, et al. 2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. Structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity. J Med Chem 1998; 41: 3276-92.
113. Panek RL, Lu GH, Klutchko SR, Batley BL, Dahring TK, Hamby JM, et al. In vitro pharmacological characterization of PD166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor. J Pharmacol Exp Ther 1997; 283: 1433-44.
114. Dimitroff CJ, Klohs W, Sharma A, Pera P, Driscoll D, Veith J, et al. Anti-angiogenic activity of selected receptor tyrosine kinase inhibitors, PD166285 and PD173074: implications for combination treatment with photodynamic therapy. Invest New Drugs 1999; 17: 121-35.
115. Trumpp-Kallmeyer S, Rubin JR, Humblet C, Hamby JM, Showalter HD. Development of a binding model to protein tyrosine kinases for substituted pyrido[2,3-d]pyrimidine inhibitors. J Med Chem 1998; 41: 1752-63.
116. Palmer BD, Smaill JB, Rewcastle GW, Dobrusin EM, Kraker A, Moore CW, et al. Structure-activity relationships for 2-anilino-6-phenylpyrido[2,3-d]pyrimidin-7(8H)-ones as inhibitors of the cellular checkpoint kinase Wee1. Bioorg Med Chem Lett 2005; 15: 1931-5.
117. Plé PA, Green TP, Hennequin LF, Curwen J, Fennel M, Allen J, et al. Discovery of a new class of anilinoquinazoline inhibitors with high affinity and specificity for the tyrosine kinase domain of c-Src. J Med Chem 2004; 47: 871-87.
118. Yezhelyev MV, Koehl G, Guba M, Brabletz T, Jauch KW, Ryan A, et al. Inhibition of SRC tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice. Clin Cancer Res 2004; 10: 8028-36.
119. Zheng R, Yano S, Matsumori Y, Nakataki E, Muguruma H, Yoshizumi M, et al. Src tyrosine kinase inhibitor, M475271, suppresses subcutaneous growth and production of lung metastasis via inhibition of proliferation, invasion, and vascularization of human lung adenocarcinoma cells. Clin Exp Metastasis 2005; 22:195-204.
120. Ali N, Yoshizumi M, FujitaY, Izawa Y, Kanematsu Y, Ishizawa K, et al. A novel Src kinase inhibitor, M475271, inhibits VEGF-induced human umbilical vein endothelial cell proliferation and migration. J Pharmacol Sci 2005; 98: 130-41.
121. Brakenhielm E, Cao R, Cao Y. Suppression of angiogenesis, tumor growth, and wound healing by resveratrol, a natural compound in red wine and grapes. FASEB J 2002; 15: 1798-800.
122. Lin MT, Yen ML, Lin CY, Kuo ML. Inhibition of vascular endothelial growth factor-induced angiogenesis by resveratrol through interruption of Src-dependent vascular endothelial cadherin phosphorylation. Mol Pharmacol 2003; 64: 1029-36.
123. Rüegg C, Hasmim M, Lejeune FJ, Alghisi GC. Anti-angiogenic peptides and proteins: From experimental tools to clinical drugs. Bioch Biophys Acta 2006; 1765: 155-77.